MiR-338-5p enhances the radiosensitivity of esophageal squamous cell carcinoma by inducing apoptosis through targeting survivin

Misun Park1,2, Hyeon-joon Yoon1, Moon Chul Kang3, Junhye Kwon1 & Hae Won Lee3

Radioresistance is a challenge in the treatment of esophageal squamous cell carcinoma (ESCC). MicroRNAs (miRNAs) are known to play an important role in the functional modification of cancer cells and recent studies have reported miRNA-mediated radiotherapy resistance. However, further research is necessary to reveal the regulation mechanisms, and treatment strategies using miRNA are yet to be established for ESCC. We compared the miRNA expression profiles of ESCC parental (TE-4) and acquired radioresistance (TE-4R) cell lines using a miRNA microarray and qRT-PCR. Our data showed that miR-338-5p, one of the target miRNA biomarkers, was significantly downregulated in TE-4R. Ectopic overexpression of miR-338-5p induced apoptosis and sensitivity to radiation treatment by interfering with survivin, which is a known inhibitor of apoptosis. Overexpression of survivin reversed miR-338-5p-induced apoptosis. Tumor xenograft experiments indicated that therapeutic delivery of the miR-338-5p mimics via direct injection into tumor mass increased sensitivity to radiation therapy. In conclusion, our findings suggest that miR-338-5p is a potential radiosensitizer and may be a therapeutic biomarker for radioresistant in ESCC.

Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers, with high incidence in East Asian countries1. Surgical resection is the primary treatment of ESCC and provides the best chance for cure. Although the 5-year survival rate remains poor, chemo-radiotherapy is of utmost importance in some cases2,3. One of the recommended treatments for ESCC is radiotherapy; however, therapeutic outcomes are not satisfactory because of tumor radioresistance owing to various mechanisms such as the DNA repair pathway and hypoxic cancer stem cells4–6. Accumulating evidence suggests that cell apoptosis may play important roles in regulating the response to radiotherapy; however, its specific contribution remains unknown7–9. Clarification of these molecular mechanisms can help identify important molecular targets that must be selectively controlled to improve the effectiveness of radiotherapy. Studies on the molecular mechanisms involved in the regulation of radioresistance revealed an association between apoptosis and tumor radioresistance, suggesting that apoptotic cell death may play an important role in determining the response to radiation in various cancers10–14. Although these studies have improved our understanding of the molecular mechanisms underlying radioresistance, the detailed mechanisms in radioresistant cell lines remain unknown and in vivo studies of radiation-induced apoptosis in ESCC have not been reported.

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by binding to the 3′ untranslated region (UTR) of their target in a sequence-specific manner, thereby decreasing gene expression15,16. Accumulating evidence indicates that miRNA expression is involved in tumorigenesis and cancer biology17,18.

1Department of Translational Research, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea. 2Department of Radiological & Medico-Oncological Sciences, Korea University of Science and Technology, Daejeon, Korea. 3Department of Thoracic Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea. Correspondence and requests for materials should be addressed to J.K. (email: jhkwon@kirams.re.kr) or H.W.L. (email: thorax@kirams.re.kr)
Several miRNAs have been correlated with patient survival and may be useful in the prediction and modification of anticancer treatments, including radiotherapy\textsuperscript{19-21}. However, miRNA expression profiling data of radioresistant ESCC cell lines are limited and potential miRNA functions in therapeutic strategies remain unclear.

In this study, we predicted that miR-338–5p is a regulator of radioresistance in ESCC based on miRNA expression profiling of ESCC parental (TE-4) and acquired radioresistance (TE-4R) cell lines. We checked for binding sites for miR-338-5p in the 3′ UTR of survivin, one of the key regulators of apoptosis inhibition. Based on our findings, we report that miR-338-5p increases radiation-induced apoptosis and enhances radiosensitivity by downregulating survivin expression.

**Results**

**Establishment of a radioresistant ESCC cell line.** To establish a radioresistant ESCC cell line, we used γ-rays to select radioresistant populations from parental TE-4 ESCC cells. TE-4 cells were exposed to fractionated radiation and surviving cells formed colonies. The colonies were pooled, and the radiation treatment was repeated (Fig. 1A). Cells derived from this selection were named TE-4R. To determine the radiosensitivity of TE-4R cells as compared with parental TE-4 cells, a clonogenic survival assay was performed. The surviving fraction of TE-4R cells was significantly larger than that of the TE-4 cells at various doses (Fig. 1B). Cell viability analysis by MTS assay at different time points (1, 3, 5, and 7 days) after irradiation with 4 Gy showed that TE-4R viability was significantly higher at day 5, and even more markedly so at day 7 after irradiation (Fig. 1C) \(p<0.05\). To evaluate the cellular response to radiation, the levels of apoptosis-related proteins were analyzed. Cleaved Poly(ADP-ribose) polymerase (PARP) and caspase3, which is considered to be a hallmark of apoptosis, was elevated in TE-4 cells than TE-4R cells as indicated by increased levels of cleaved PARP and caspase3 in the former (Fig. 1D). These data indicated that TE-4R cells are more resistant to cell death than the parental cells after irradiation.

**MiR-338-5p is downregulated in radioresistant ESCC cells.** To identify miRNAs that regulate radiosensitivity in ESCC cell lines, we used the NanoString nCounter miRNA expression assay. The miRNA expression array indicated that 20 miRNA were increased (fold change > 1.5) and 49 miRNA were decreased (fold change < 1.5) in TE-4R cells as compared to their parental cell line (Fig. 2A). We selected miR-338-5p for further analysis because its function and mechanism in radiosensitization have not been characterized. MiR-338-5p was downregulated in the TE-4R cell line (fold change = −5.1). Real-time PCR analysis confirmed the microarray data (Fig. 2B). To investigate the effect of miR-338-5p as a radiosensitizer, TE-4 cells were transiently transfected...
with control (miR-con) or miR-338-5p mimic (miR-338), and their survival after irradiation was determined. Western blot results confirmed that transfection was successful (Fig. S1). A clonogenic survival assay showed that miR-338-5p significantly decreased the surviving cell fraction as compared to miR-con (Fig. 2C). The effect of miR-338-5p expression on cell growth after irradiation was also examined by MTS assay; miR-338-5p-treated cells showed reduced numbers as compared to miR-con-treated cells at 3, 5, and 7 days ($p < 0.05$) (Fig. 2D). Taken together, these results demonstrated that miR-338-5p expression in ESCC cells significantly decreases radiore-sistance in vitro; thus, miR-338-5p can sensitize ESCCs cells to irradiation.

**MiR-338-5p inhibits radiation-induced apoptosis.** Our and other groups have shown that apoptosis is one of the major factors regulating radioresistance in ESCC. To investigate whether miR-338-5p acts as a radiosensitizer through regulation of apoptosis, we examined apoptosis following irradiation. MiR-338-5p-transfected TE-4 and TE-14 cells showed significant increases in cleaved PARP and caspase3 as compared to controls after irradiation, from 31.62% to 40.58% in TE-4 and from 45.32% to 51.8% in TE-14 (Fig. 3A,B). To confirm the apoptotic effect of miR-338-5p, we inhibited miR-338-5p using miR-338 inhibitor (Anti-338). Anti-338 repressed cleaved PARP and caspase3 expression after irradiation in both cell lines (Fig. 3C). Furthermore, anti-338-transfected groups decreased from 33.87% to 15.94% for TE-4 and from 33.39% to 23.67% for TE-14 (Fig. 3D). On the basis of these findings, we concluded that miR-338-5p can sensitize ESCCs cells to irradiation.

**MiR-338-5p regulates the expression of survivin.** To understand how miR-338-5p modulates radiation-induced apoptosis, we analyzed target genes of miR-338-5p predicted by TargetScan (www.targetscan.org) and miRanda (www.microrna.org). Most notably, one of the predicted targets is survivin, which is known to inhibit apoptosis. Previous studies have suggested that survivin is important in the development of radioresistance through the regulation of apoptosis. When compared with TE-4 cells, TE-4R cells exhibited much higher survivin expression (Fig. 4A). Thus, we assumed that miR-338-5p targets survivin. To analyze the targeted regulation of survivin by miR-338-5p in ESCC cells further, the miR-338-5p level was manipulated by transfecting
the cells with miR-338-5p mimic and inhibitor. MiR-338-5p mimic transfection significantly reduced survivin expression, whereas its expression increased in anti-338-transfected cells as compared with their controls, in both the TE-4 and TE-14 cell lines (Fig. 4B,C). To confirm survivin as a direct target of miR-338-5p, we constructed a luciferase reporter plasmid containing the binding site of the survivin 3′ UTR (3′ UTR WT) and one harboring a deletion of the binding site (3′ UTR muta). We co-transfected these plasmids with miR-con or miR-338 into TE-4 cells. The results revealed significantly reduced luciferase activity in cells transfected with 3′ UTR WT- and miR-338, whereas the mutant form did not affect luciferase activity (Fig. 4D). These findings suggested that survivin is a direct target of miR-338-5p.

Survivin overexpression rescues cells from apoptosis induced by miR-338-5p. To confirm the interaction between miR-338-5p and survivin, we silenced the latter using siRNA and examined the effect on apoptosis. Western blot assay and flow cytometry analysis of Annexin V-stained cells showed that the knockdown of endogenous survivin expression could imitate the effects associated with miR-338-5p overexpression, including increased cleaved PARP and caspase3 expression levels and promotion of apoptosis (Fig. 5A and B). To clarify whether apoptosis induction by miR-338-5p is mediated through suppressing survivin expression, a pCMV survivin expression plasmid was constructed. A rescue experiment was conducted to explore whether survivin could functionally reverse radiation-induced apoptosis by miR-338-5p. The pCMV-survivin vector and pCMV control vector were transfected into TE-4 cells with miR-con or miR-338-5p, and the cells were examined by flow cytometry after irradiation. The level of apoptotic cells was decreased in cells overexpressing survivin as compared to control cells transfected with miR-338-5p (Fig. 5C). This rescue experiment revealed that survivin can reverse the apoptosis induced by miR-338-5p.

MiR-338-5p enhances radiosensitivity of ESCC in xenograft models. To explore whether miR-338-5p enhances radiosensitivity in vivo, we generated subcutaneous tumors in nude mice using TE-4 cells. As illustrated in Fig. 6A, control or miR-338-5p mimic were injected into the tumors 4 times at 1-week intervals before and after ionizing radiation of 6 Gy, and tumor size was measured every 3 days. After irradiation, control tumors continued to increase in volume; however, miR-338-5p-injected TE-4 tumors grew evidently slower (Fig. 6B). Additionally, survivin expression was downregulated in miR-338-transfected xenografts (Fig. 6C). Taken together, these results demonstrated that miR-338-5p expression obviously decreases radiosensitivity in vivo, suggesting that in vivo administration of miR-338-5p mimic has considerable potential for radiosensitization.
Radiotherapy plays an important role in the treatment of esophageal cancers as part of combined-modality therapy together with chemotherapy and surgery. This treatment approach has improved tumor control and survival rates. However, tumor recurrence because of radioresistance occurs in a high proportion of patients; therefore, therapeutic strategies to improve the response to radiation in ESCC need to be developed. Here, we identified miR-338-5p as a radiosensitizer. Additionally, we found the miR-338-5p target survivin to be an important inhibitor of radiation-induced apoptosis (Fig. 6D).

Abundant miRNAs regulate a wide range of biological processes in cancers. Using a miRNA expression profiling approach, we identified miR-338-5p as a downregulated miRNA in radioresistant ESCC. In a previous study, miR-338-5p was considered to function as an oncomiR by inhibiting PIK3C3 expression and autophagy in colorectal cancer. However, miR-338-5p might have different functions in different cancers. Our results demonstrated that miR-338-5p acts as a radiosensitizer through inhibition of apoptosis in ESCC. Results from several other groups have confirmed miRNAs to be involved in the radioresistance of ESCC. Huang et al. identified miR-21 as an activator of radioresistance through inhibition of PTEN, and Su et al. recently found a set of miRNAs aberrantly expressed in acquired radioresistant ESCC cells that conferred resistance through the Wnt/B-catenin signal pathway. Although these studies reported on miRNAs associated with radioresistance in ESCC, our study is the first to show that miR-338-5p as radiosensitizer inhibits radiation-induced apoptosis in vitro and in vivo.

Discussion

Survivin is a direct target of miR-338-5p in ESCC cells. (A) Levels of survivin were compared in parental TE-4 cells and radioresistance TE-4R cells. β-actin served as a loading control. (B,C) MiR-338, anti-338, or control miR were transfected into TE-4 and TE-14 cells. After 72 h, expression levels of survivin and β-actin were analyzed by western blot analysis. (D) Top, the predicted miR-338-5p-binding sites in the survivin (3′ UTR WT) and mutant (3′ UTR muta) 3′ UTR are shown; down, 3′ UTR WT or 3′ UTR muta dual luciferase reporter vector was cotransfected into TE-4 cells with miR-con or miR-338, and firefly luciferase activity normalized to Renilla luciferase activity is shown. Data are the means ± SD, p < 0.05.
We showed that survivin expression was markedly enhanced in the radioresistant cell line as compared to the parental cells. We and others previously showed that survivin is associated with radioresistance in pancreatic cancer, rectal cancer, head and neck squamous carcinoma, as well as lung cancer\(^2\)\(^2\), \(^2\)\(^3\), \(^2\)\(^8\), \(^2\)\(^9\). Survivin is tightly associated with stemness-promoting pathways such as Notch\(^3\)\(^0\), Oct4, and STAT3\(^3\)\(^1\). Moreover, survivin was shown to be a major target of different pro-survival signaling pathways, such as the PI3K/AKT pathway\(^3\)\(^2\). These pathways are known to control radiosensitivity; thus, survivin might induce radioresistance in ESCC through the regulation of these signaling pathways. Additionally, accumulation of survivin and interaction with components of the DNA-double-strand break (DSB) repair machinery in glioblastoma cells indicated that survivin regulates DSB repair, significantly improving survival in these cells\(^2\)\(^5\). It will be interesting to study the different roles of survivin, including not only the inhibitory effect on caspase activity during apoptosis but also functions in DNA damage repair in ESCC radioresistant cells. Future studies are required to test this hypothesis.

To the best of our knowledge, this is the first report of the roles of miR-338-5p and survivin in radioresistance of ESCC. We reported a novel role for miR-338-5p as a key regulator of apoptosis and showed that miR-338-5p sensitizes ESCC to irradiation by inhibiting survivin expression suggesting miR-338-5p as a potential therapeutic strategies for improving the response of ESCC patients to radiation therapy.

**Methods**

**Establishment of a radioresistant cell line and cell culture.** TE-4 and TE-14 ESCC cells were purchased from RIKEN (RIKEN, Saitama, Japan). To establish a radioresistant TE-4 cell line, cells were treated with 2 Gy per week for 15 weeks. The surviving cells were treated with 4 Gy per week for 15 more weeks. Upon completion of the radiation treatment, surviving cells were defined as the radioresistant TE-4 cell line, named TE-4R. All ESCC cells were cultured in RPMI-1640 (Corning, New York, NY, USA) supplemented with 10% FBS (Gibco, Grand Island, NY, USA) and antibiotics (100 units/ml penicillin and 100μg/ml streptomycin, Corning) at 37 °C in an atmosphere of 5% CO\(_2\)/95% air.

**Irradiation and clonogenic assay.** TE-4 and TE-4R cells were seeded at 2 × 10\(^3\) cells per well in 6-well culture plates, cultured for 24h, and irradiated with different radiation doses (0, 2, 4, 6, and 8 Gy) using a \(^{137}\)Cs γ-ray source (Atomic Energy of Canada Ltd, Chalk River, Canada) at a dose rate of 3.81 Gy/min. After 14 days of culture, the cells were fixed, stained with 2% crystal violet, and cell colonies were counted using the ImageJ software.
Transfection. One day before transfection, cells were seeded in 6-well plates and cultured to 60–80% confluence. Then, the cells were treated with 50 nM control microRNA, miR-338-5p mimic; 20 nM siNC or siSurvivin (Bioneer, Daejeon, Korea); or 1 μg survivin expression plasmid or vehicle (Origene, Rockville, MD, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 6 h, the cells were transferred to complete growth medium. On the third day after transfection, the cells were harvested and used in further experiments.

MiRNA expression profiling using a NanoString array. MiRNAs were prepared using a miRNeasy Mini kit (Qiagen, Hilden, Germany) and hybridized to the array in the nCounter miRNA Expression Assay (NanoString Technologies, Seattle, WA, USA) following the manufacturer’s instructions.

Real-time PCR. MiRNAs were quantified using the miScript SYBR Green PCR kit (Qiagen) with specific primers for miR-338-5p and U6 (Qiagen). Quantitative PCRs were run on a 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The reaction mixtures were incubated at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C 30 s, and 72 °C 30 s. The expression level was determined by the $2^{-\Delta\Delta Ct}$ method.

Flow cytometry analysis of apoptosis. Irradiated cells were stained with fluorescein isothiocyanate (FITC)-labeled annexin V/propidium iodide (PI) using an apoptosis detection kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions, and were analyzed by flow cytometry (BD Biosciences).

Western blotting. For western blot analysis, cells were washed with cold PBS and lysed in RIPA buffer (Thermo Fisher Scientific, Grand Island, NY, USA). Proteins were quantified using the Bradford method and equal amounts of protein were resolved by SDS-PAGE and analyzed by western blotting as previously described. The membranes were incubated with primary antibodies against cleaved PARP, caspase3, survivin (Cell Signaling Technology, Beverly, MA, USA) and β-actin (Sigma-Aldrich, St. Louis, MO, USA) overnight at 4 °C and with a secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. Proteins were visualized using enhanced chemiluminescence (Thermo Fisher Scientific). Western blot images were analyzed with a LAS-4000 mini (GE Healthcare Life Sciences, Uppsala, Sweden) and Bio-Rad ChemiDoc (Bio-Rad, Richmond, CA, USA).

Figure 6. Upregulation of miR-338-5p decreases TE-4 cell radioresistance in vivo. (A) Schedule of administration of miR-338-5p to and irradiation of TE-4 xenografts. TE-4 cells were inoculated into the backs of nude mice (n = 9), and when tumor volumes reached 100 mm³, treatment by intratumoral injection of 10 μg jetPEI/miR-con or jetPEI/miR-338 complexes was started. Arrows show the days on which injections of jetPEI/miR complex were administered. (B) Tumor volumes expressed as percentages (%) relative to the volume at the time of the first miR injection (day 0). Error bars indicate the SD (n = 9). (C) On day 26 after injection, the mice were sacrificed and survivin expression was detected by western blotting. (D) Schematic illustration of the difference between radiosensitivity and radioresistance in ESCC.
Cell proliferation assay. Cells were seeded in 96-well plates and allowed to attach for 24 h. Then, the cells were irradiated with 4 Gy. At various time points, 10 μl of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) of the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA) was added to 100 μl of culture media for 1 h. The absorbance at 490 nm was read using a plate reader.

Dual luciferase reporter assay. TE-4 cells were seeded into 6-well plates one day before transfection. The cells were transfected with 1 μg of pmiRGLO vector (Promega) containing predicted miR-338-5p-binding sites of the survivin 3′ UTR and 50 nM microRNA mimic using Lipofectamine 2000. pRL-TK, which encodes Renilla luciferase, was included in all transfections to normalize for transfection efficiency. At 48 h after transfection, assays were performed using a dual luciferase reporter system (Promega) according to manufacturer’s instructions. Firefly luciferase activity was normalized to that of Renilla, and then compared with those of the respective controls.

Animal experiments. Female nude mice at 6 weeks of age were subcutaneously injected with 1 × 10^7 TE-4 cells into the right flank of the back. At 7 days post-injection, 1.6 μl JetPEI and 10 μg miR-con or miR-338-5p were directly injected into the tumor, and injections were repeated every week for 4 weeks. Then, the mice were irradiated with a single dose of 6 Gy using an X-RAD 320 X-ray irradiator (Soflex, Goyang, Korea) at a dose rate of 2 Gy/min. This study was carried out in accordance with relevant guidelines and regulations. The animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Korea Institute of Radiological and Medical Sciences (protocol number: KIRAMS 2016-0032). The animal care facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.

Statistical analysis. Data obtained from at three experiments are expressed as the mean ± standard deviation. Statistical significance of differences was analyzed by Student’s t-test, and p < 0.05 was considered significant.

References
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7–30 (2016).
2. Pennathur, A., Gibson, M. K., Jove, B. A. & Luketich, J. D. Oesophageal carcinoma. The Lancet 381, 400–412 (2013).
3. Rustgi, A. K. & El-Serag, H. B. Esophageal carcinoma. New England Journal of Medicine 371, 2499–2509 (2014).
4. Kim, J. I. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Reviews Cancer 5, 516–525 (2005).
5. Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature reviews Cancer 15, 409–425 (2015).
6. Chang, L. et al. Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell death & disease 4, 6875 (2013).
7. Saunders, N. A. et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular medicine 4, 675–684 (2012).
8. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. nature 444, 756–760 (2006).
9. Park, M., Yoon, H.-j., Kang, M. C., Kwon, J. & Lee, H. W. PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma. Tumor Biology 37, 14217–14224 (2016).
10. Chang, L. et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHE and HR repair pathways. Cell death & disease 5, e1437 (2014).
11. Pan, X. et al. SHP-1 overexpression increases the radioresistance of NPC cells by enhancing DSB repair, increasing S phase arrest and decreasing cell apoptosis. Oncology reports 33, 2999–3005 (2015).
12. Yang, C.-F. et al. Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer letters 344, 260–271 (2014).
13. Squatrito, M. et al. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer cell 18, 619–629 (2010).
14. Kurrey, N. K. et al. Snail and slug mediate radiosensitivity and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem cells 27, 2059–2068 (2009).
15. Shukla, G. C., Singh, J. & Barik, S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol 3, 83–92 (2011).
16. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233, doi:10.1016/j.cell.2009.01.002 (2009).
17. Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nature reviews cancer 15, 321–333 (2015).
18. Farazi, T. A., Hoell, J. I., Morozov, P. & Tuschl, T. In MicroRNA Cancer Regulation 1–20 (Springer, 2013).
19. Wang, P. et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 145, 1133–1143 e1112, doi:10.1053/j.gastro.2013.07.048 (2013).
20. Weidhaas, J. B. et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer research 67, 1111–1116 (2007).
21. Su, H. et al. Identification of microRNAs involved in the radioresistance of esophageal cancer cells. Cell biology international 38, 318–325 (2014).
22. Rodel, F. et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer research 65, 4881–4887 (2005).
23. Khan, Z. et al. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 96, 267–273, doi:10.1016/j.radonc.2010.06.005 (2010).
24. Rhodes, A. & Hillen, T. Mathematical Modeling of the Role of Survivin on Dedifferentiation and Radioresistance in Cancer. Bull Math Biol 78, 1162–1188, doi:10.1007/s11538-016-0177-x (2016).
25. Reichert, S. et al. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101, 51–58, doi:10.1016/j.radonc.2011.03.037 (2011).
26. Fu, J.-A. et al. Characterization of a colorectal cancer migration and autophagy-related microRNA miR-338-5p and its target gene PIK3C3. Biomarkers and Genomic Medicine 5, 74–78 (2013).
27. Huang, S. et al. Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Diseases of the Esophagus 26, 823–831 (2013).
28. Asanuma, K. et al. Survivin as a radioresistance factor in pancreatic cancer. Japanese journal of cancer research 91, 1204–1209 (2000).
29. Lu, B. et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. *Cancer research* **64**, 2840–2845 (2004).

30. Ju, J.-h. et al. HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. *Biochemical Journal* **451**, 123–134 (2013).

31. Wen, K. et al. Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. *Cancer letters* **333**, 56–65 (2013).

32. Zhao, P. et al. Regulation of survivin by PI3K/Akt/p70S6K1 pathway. *Biochemical and biophysical research communications* **395**, 219–224 (2010).

33. Kim, J.-H. et al. Protein tyrosine kinase 7 plays a tumor suppressor role by inhibiting ERK and AKT phosphorylation in lung cancer. *Oncology reports* **31**, 2708–2712 (2014).

Acknowledgements
This study was supported by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science, ICT and Future Planning, Republic of Korea (1711045543;1711045540/50462-2017).

Author Contributions
Misun Park performed a majority of the experiments and wrote the manuscript. Junhye-Kwon and Hae-won Lee designed research and wrote the manuscript text. Hyeon-joon Yoon and Moon Chul Kang performed experiments. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10977-9

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017